Role of Anti-PF4/Heparin Antibodies in Recurrent Thrombotic Events after Acute Coronary Syndromes

We postulated that patients with recent acute coronary syndromes and antibodies to the platelet factor 4/heparin complex would have an increased risk of myocardial infarction (MI), even in the absence of thrombocytopenia. We analyzed sera from patients enrolled in the placebo/unfractionated heparin arm of the GUSTO IV-ACS trial who had a high likelihood of prior heparin exposure. We selected 109 patients without thrombocytopenia with the 30-day primary endpoint (death, MI, or revascularization) and 109 age-, gender-, and race-matched controls who did not achieve the primary endpoint. Twenty-three of 218 patients (10.6%) had anti-PF4/heparin antibodies. Patients with anti-PF4/heparin were more likely to have death or MI (30.4% vs. 11.3%, p = 0.011) or MI (21.7% vs. 6.2%, p = 0.008) than patients who were negative for the antibody. Antibody-positive patients had higher levels of sVCAM-1 (892 ± 263 μg/L vs. 780 ± 228 μg/L; p = 0.04) and sICAM-1 (246 ± 50 μg/L vs. 222 ± 71 μg/L; p = 0.02) than antibody-negative patients. In a multiple logistic regression model that included inflammatory markers and clinical risk factors, antibodies to PF4/heparin were a strong predictor of 30-day MI (odds ratio, 9.0; 95% confidence intervals, 2.1 to 38.6; p < 0.01), with IL-6 being the only other predictor (odds ratio, 1.1; 95% confidence intervals, 1.0 to 1.2; p = 0.03). Antibodies to the platelet factor 4/heparin complex are a novel, independent predictor of MI at 30 days in patients presenting with acute coronary ischemic syndromes. Antibodies to PF4/heparin are a stronger predictor of MI than clinical characteristics or inflammation markers.

Heparin - antibodies - platelets - inflammation - myocardial infarction

REFERENCES

• 1 Chong B E. Heparin-induced thrombocytopenia.  J Thromb Haemost. 2003;  1 1471-1478
• 2 Warketin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost. 1998;  79 1-7
• 3 Amiral J, Bridey F, Wolf M et al.. Antibodies to macro platelet factor 4-heparin complexes in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
• 4 Walz D A, Wu V Y, deLamo R, Dene H, McCoy L E. Primary structure of human platelet factor 4.  Thromb Res. 1997;  11 893-898
• 5 Rao K A, Niewiarowski S, Ames P et al.. Effect of heparin on the in vivo release and clearance of human platelet factor 4.  Blood. 1983;  61 1208-1214
• 6 Suh J S, Aster R H, Visentin G P. Antibodies from patients with heparin-induced thrombocytopena/thrombosis recognize different epitopes on heparin.  Blood. 1998;  91 916-922
• 7 Amiral J, Meyer D. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Marcel Dekker 2002: 137-148
• 8 Arepally G M, Mayer M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.  Blood. 2001;  98 1252-1254
• 9 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia.  N Engl J Med. 1987;  316 581-589
• 10 Visentin G P, Ford S E, Scott J P et al.. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest. 1994;  93 81-88
• 11 Williams R T, Damaraju L V, Mascelli M A et al.. Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.  Circulation. 2003;  107 2307-2312
• 12 Simoons M L. GUSTO IV-ACS Investigators . Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.  Lancet. 2001;  357 1915-1919
• 13 Mattioli A V, Bonetti L, Sternieri S et al.. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1-year follow-up.  Ital Heart J. 2000;  1 39-42